Screen Reader Access
Dr. Fayaz A Malik
Sr. Principal Scientist
Cancer Pharmacology Division
CSIR-Indian Institute of Integrative Medicine Sanat Nagar Srinagar
Email: fmalik@iiim.res.in
Bio Sketch
Dr. Malik is a Pr. Scientist in the Division of Cancer Pharmacology at CSIR-Indian Institute of Integrative Medicine. Dr. Malik earned a Ph.D. from Punjab University, Punjab India and did his postdoctoral work with Prof. Dr. Max A. Wicha at the University of Michigan Ann Arbor, USA. Dr. Malik joined the CSIR-IIIM, as a scientist in 2008 and has been promoted to the positions of Sen. Scientist in 2011 and Pr. Scientist in 2015
Research Statement
Major research interest of his group is to understand the fundamental regulatory mechanisms associated with Tumor metastasis and therapeutic resistance. Metastasis remains the major cause of cancer associated deaths and a huge clinical challenge with no therapeutic intervention. His current research goals are to understand the underlying mechanisms of cancer stem cells and metastasis in triple-negative breast cancer (TNBC) to identify the new targets, and identify small molecules against highly aggressive and drug resistant breast cancers.
Education
| Degree | Subjects | University | Qualifying Year |
| Phd | Life Science | Punjab University | 2009 |
| M.Sc | Biotechnology | Punjab University | 2001 |
Position Held
| Position Held | Period | Organization |
| Sr. Principal Scientist | 02.04.2020 TO Present | CSIR-IIIM |
| Principal Scientist | 02.04.2015 TO 02.04.2020 | CSIR-IIIM |
Area of Expertise
- Cancer metastasis, drug discovery, Stem Cell Biology, Autophagy, Neurobiology (depression)
Projects
- Uncovering the role of stem cells in tumor invasion and metastasis.
- Targeting drug resistant cancer stem cells by using small molecules
Publications
| Sno. | Author | Title | Journal |
|
1 |
Wadhwa B, Paddar M, Khan S, Mir S, Clarke P, Grabowska A, Vijay D, Vishwakarma R, Malik F*
|
AKT isoforms have discrete expression in Triple Negative breast cancers and roles in cisplatin sensitivity |
Oncotarget 2020
|
|
2 |
Korkaya H, Kim G, Davis A, Malik F, Henry N, Ithimakin S, Quraishi A, Tawakkol…., Hassan K, Zen Q, Clouthier SG, Wicha M. | Activation of an IL6 Inflammatory Loop Mediates Trastuzumab Resistance in HER2+ Breast Cancer by Expanding the Cancer Stem Cell Population. | Mol. Cell
(2012)
|
|
3 |
Pathania AS, Guru SK, Kumar S, Kumar A, Ahmad M, Korkaya H and Malik F* |
Interplay between cell cycle and autophagy induced by boswellic acid analog |
Scientific Reports (2016) 6: 33146
|
|
4 |
Ithimakin S#, Day K#, Malik F#, Zen Q, Dawsey J, Bersano-Begey F, Quraishi…… Korkaya H, Wicha MS | HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: Implications for efficacy of adjuvant trastuzumab |
Cancer Research (2013) 73:1635-46
|
|
5 |
Guru SK, Pathania AS, Kumar S, Ramesh D, Kumar M, Rana S, Kumar A, Malik F, Shah BA, Saxena AK, Vishwakarma RA, Bhushan S. | Secalonic Acid-D Represses HIF1α/VEGF-Mediated Angiogenesis by Regulating the Akt/mTOR/p70S6K Signaling Cascade. | Cancer Research (2015) 75(14):2886-96 |
|
6 |
Pathania A, Wani Z, Guru S, Kumar S, Bhushan S, Korkaya H, Seals D, Kumar A, Mondhe D, Ahmed Z, Chandan B, Malik F* | The anti-angiogenic and cytotoxic effects of the boswellic acid analog BA145 are potentiated by autophagy inhibitors. | Molecular Cancer
(2015)14:6
|
|
7 |
Kim G, Ouzounova M, Quraishi A, Davis A, Tawakkol N, Clouthier S, Malik F, …. Wicha MS, Korkaya H. | SOCS-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model | Oncogene
(2014): 1–10 |
|
8 |
Singh U, Chashoo G, Khan S, Mahajan P, Nargotra A, Mahajan G, Singh A, Sharma A, Mintoo M, Guru SK, Kumar V, Mir S, Bharate S, Bhushan S, Malik F*, Mignani S, Vishwakarma R, Singh P* | Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model. |
J Medicinal Chem. (2017) 60:9470-89
|
|
9 |
Kumar S, Pathania A, Guru S, Kumar A, Bhushan S and Malik F*. | Autophagy triggered by Magnolol derivative negatively regulates angiogenesis. | Cell Death and Disease
(2013) 4, e889
|
|
10
|
Ke J, Zhao Z, Hong S, Bai S, He Z, Malik F, Xu J, Zhou L, Chen W, Wu X, Lan P, Yi Y, Ginestier C, McDermott S, Clouthier SG, Wicha MS, Liu S | Role of MicroRNA221 in regulating normal mammary epithelial hierarchy and breast cancer stem-like cells | Oncotargets
(2015) 6(6):3709-21
|
Patents
| Inventors/ Contributors | Title | Description | Year |
| ThatikondaThansha, Kumar Suresh, Singh Umed, MahajanPriya, MahajanGirish, NagrotaAmit, Malik, Fayaz, MondheDilip, Vishwakarma Ram, Singh parvinder pal | Novel 1,3,5- Triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof | US20170342049, WO/2016/079760A4, EP3221307A1 | 2016 |
| A. Khajuria, A. Gupta, S.Singh, F. Malik, Jaswant Singh, KL Bedi, KA Suri, NK Satti, OP Suri, GN Qazi, VK Srinivas, Gopinathan, K Ella |
Iridoid glycoside composition |
EP1837027A1, US20070275006
|
2007 |
| Qazi, GhulamNabi, TanejaSubash Chandra.; Singh, Jaswant; SaxenaAjit Kumar; Sethi Vijay Kumar; Shah Bhahwal Ali, Kumar Ajay, Andotra Samar Singh, Malik, Fayaz; MuthiahShanmugavel, Agarwal, Satyam Kuma | Use of semi synthetic analogues of boswellic acids for anticancer activity | US20090298938 | 2009 |
Awards and Honours
- 2015 National Bioscience Award (NBA) in Biological Sciences. by. Department of Biotechnology (DBT) Government of India.
- 2014 Golden Jubilee (SWARANAJA YANTI) Fellowship Award in Biological , by Department of Science and Technology (DST) Govt. of India
- 2010 Young Scientist Award for Biological Sciences, of Jammu and Kashmir,
- 2009 CSIR Young Scientist Award (CSIR YSA_2009) for Biological Sciences, India.
Students
| Photo | Name | Area of Interest | Education |
 |
Nadiem Bhat |
Focus is to study contrasting transcriptomic conditions using RNA-Seq technologies in highly aggressive cancers to identify new therapeutic targets by using CSCs, CTCs and clinical samples. I am also involved in virtual screening of small molecule against various biological targets. |
Postdoc fellow/RA |
 |
Baseerat Hamza | Research interests is to study proteome and metabolome changes of highly aggressive and therapeutically changing breast cancer subtypes, by using high throughput mass spectrometry technology. Aim is to try to understand the dynamics of functional protein networks to delineate biological mechanisms of disease. | DST-SRF/Research Associate |
 |
Masroor Ahmed |
Research interest is to explore the new therapeutic targets and target specific agents in drug resistance HER2 Breast Cancer. |
PhD, CSIR-SRF |
 |
Sameer Mir | Research focus is on identify small molecule stem cell modulators. Currently working on pre-clinical development of identified small molecule targeting drug resistant Cancer Stem Cells in Tripe Negative Breast Cancers (TNBCs). | PhD, UGC-SRF |
 |
Sameer Ullah khan |
Research interest is towards understanding the role of authophagy in anikious resistance Breast cancer cells and identifying their survival mechanism. |
PhD, CSIR-SRF |
 |
Loveleena kaur Anand | Research interest is to identify potent anti-depressant agents from natural products by using cellular and animal models and exploring the biological mechanism of the disease | PHD, DST-INSPIRE SRF |
 |
Mir Shahid |
Research interest is to explore the metastatic potential of tumor suppressors and their role in clinical manifestation of Breast cancer subtypes TNBCs. |
PhD, CSIR-SRF |
 |
Kaneez Fatima | Research interest is to understand the role of critical interaction between immune system and breast cancer metastasis. | PhD,UGC-JRF |
ALUMNI
Dr. Anup Singh Pathania ( Currently Postdoctoral fellow at University of California USA)
Dr. Suresh Kumar Thakur
(Currently Postdoctoral Fellow at University of New Mexico USA)
Mr. Ubaid Makhdoomi (Currently Ass. Prof at Govt. Degree College J&K)
Mr. Abid Akbar ( Current at Govt. of J&K)
Dr. Bhumika Wadhwa (Submitted PhD thesis)
Ms. Sonia Sharma (Submitted PhD Thesis)